869681-70-9

Basic information

• Product Name: 4-Boc-3(R)-morpholinecarboxylic acid
• Synonyms: (R)-N-Boc-morpholine-3-carboxylic acid;4-Boc-3(R)-morpholinecarboxylic acid;(R)-Morpholine-3,4-dicarboxylic acid 4-tert-butyl ester;3,4-Morpholinedicarboxylic acid, 4-(1,1-dimethylethyl) ester, (3R)-;(R)-4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid;(3R)-4-[(tert-butoxy)carbonyl]Morpholine-3-carboxylic acid;(R)-N-tert-butoxycarbonylMorpholine-3-carboxylicacid;(R)-4-N-Boc-3-Morpholinecarboxylic acid
• CAS NO: 869681-70-9
• Molecular Formula: C₁₀H₁₇NO₅
• Molecular Weight: 231.25
• Product Categories: Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks;Morpholines/Thiomorpholines;New Products for Chemical Synthesis;C4 to C10
• Mol File: 869681-70-9.mol

Chemical Properties

• Melting Point: 181℃
• Boiling Point: 369.5 °C at 760 mmHg
• Flash Point: 177.3 °C
• Appearance: White/Powder
• Density: 1.23 g/cm³
• Vapor Pressure: 1.8E-06mmHg at 25°C
• Refractive Index: 1.492
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 3.53±0.20(Predicted)
• CAS DataBase Reference: 4-Boc-3(R)-morpholinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Boc-3(R)-morpholinecarboxylic acid(869681-70-9)
• EPA Substance Registry System: 4-Boc-3(R)-morpholinecarboxylic acid(869681-70-9)

Safety Data

• RIDADR: UN2811
• HazardClass: 6.1
• Hazardous Substances Data: 869681-70-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H17NO5/c1-10(2,3)16-9(14)11-4-5-15-6-7(11)8(12)13/h7H,4-6H2,1-3H3,(H,12,13)/t7-/m1/s1

Upstream product

• 885321-46-0 (R)-methyl N-tert-butoxycarbonylmorpholine-3-carboxylate 
• 1235387-14-0 C₁₃H₁₇NO₃ 
• 1207428-21-4 C₈H₁₁N*C₁₀H₁₇NO₅ 
• 885321-34-6 (R)-3-(tert-butyldiphenylsilyloxymethyl)morpholine 
• 714971-28-5 (S)-3-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester 
• 1373883-17-0 (S)-2-chloroacetylamino-3-hydroxypropionic acid ethyl ester 
• 211053-50-8 (S)-3-(hydroxymethyl)morpholine 

Downstream Products

• 1187933-47-6 methyl (R)-morpholine-3-carboxylate 
• 1189569-40-1 (2R)-5-{(1E)-3-[(7R,9aR)-7-(3,5-difluorophenyl)-9-oxohexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]prop-1-en-1-yl}-1,3-dihydrospiro[indene-2,3 '-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 5 
• 1189570-08-8 (9aR)-8-allyl-7(R)-(3,5-difluorophenyl)hexahydropyrazino[2,1-c][1,4]oxazin-9(6H)-one 
• 1189570-10-2 (9aR)-8-allyl-7(S)-(3,5-difluorophenyl)hexahydropyrazino[2,1-c][1,4]oxazin-9(6H)-one 
• 1189570-09-9 methyl 4-[2-(3,5-difluorophenyl)-2-oxoethyl]morpholine-3(R)-carboxylate 
• 1190115-55-9 (R)-(4-(4-(4-(2-(isopropylsulfonyl)phenylamino)pyrazolo[1,5-a][1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenyl)piperidin-1-yl)(morpholin-3-yl)methanone 
• 911223-07-9 (R)-3-{4-chloro-2-[3-(5-methyl-pyrazin-2-yl)-ureido]-phenoxymethyl}-morpholine-4-carboxylic acid tert-butyl ester 
• 911223-05-7 (R)-3-(4-chloro-2-nitro-phenoxymethyl)-morpholine-4-carboxylic acid tert-butyl ester 
• 911223-06-8 (R)-3-(2-amino-4-chloro-phenoxymethyl)-morpholine-4-carboxylic acid tert-butyl ester 
• 1257850-86-4 (R)-3-formylmorpholin-4-carboxylic acid tert-butyl ester 
• 1410811-09-4 (S)-tert-butyl-3-((S)-1-(4-(((1,2-trans)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamido)-2-methoxy-2-oxoethyl)morpholine-4-carboxylate 
• 1410810-92-2 (S)-tert-butyl-3-(2-methoxy-2-oxoethyl)morpholine-4-carboxylate 

Relevant articles and documents

Preparation method of chiral N-tert-butyloxycarborylmorpholine-3-carboxylic acid

The invention provides a preparation method of chiral N-tert-butyloxycarborylmorpholine-3-carboxylic acid, which comprises the following steps: (1) carrying out an amino protection reaction on chiralserinamide and an amino protective agent to obtain a com

Chiral 3 - morpholine methyl alcohol and 3 - morpholine a acid preparation method of the compound

The invention discloses a novel method for preparing chiral 3-morpholine methanol and 3-morpholine formic acid compounds. The method comprises the following steps: taking chiral serine as an initial material to obtain a serine ester (III) from a catalyst by esterification; reacting with halogen acetyl halide under an alkaline condition to obtain a compound (IV); obtaining a compound (V) by hydroxyl protection; adding a reducing agent to restore the ester into alcohol (VI); carrying out cyclization under the alkaline condition to obtain a compound (VII); obtaining a target product chiral 3-morpholine methanol compound (I) by amide reduction, hydroxyl deprotection and N protection; obtaining a chiral 3-morpholine formic acid compound (II) by oxidation. The method has the advantages of being low in cost, friendly to environment, simple to operate, high in yield, high in product purity and the like, the used reagent is simple and safe, and an intermediate in the reaction of each step does not need to be further purified, so that the experiment operation is greatly simplified, the production cost is reduced, and the method is applicable to industrial production.

CRYSTALLINE FORMS OF A PYRIDINE DERIVATIVE

The invention relates to 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form or in a solvate thereof, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

Synthesis of chiral C/N-functionalized morpholine alcohols: Study of their catalytic ability as ligand in asymmetric diethylzinc addition to aldehyde

A broad variety of chiral C/N-functionalized morpholine alcohols sharing a common structural motif in the 3-(hydroxymethyl)morpholine 6 were prepared from enantiomerically pure serine for the purpose of studying their catalytic ligand properties. The asym